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abstract
 
Central core disease (CCD) is a human myopathy that involves a dysregulation in muscle Ca
 
2
 
 
 
 ho-
meostasis caused by mutations in the gene encoding the skeletal muscle ryanodine receptor (RyR1), the protein
that comprises the calcium release channel of the SR. Although genetic studies have clearly demonstrated linkage
between mutations in RyR1 and CCD, the impact of these mutations on release channel function and excitation-
contraction coupling in skeletal muscle is unknown. Toward this goal, we have engineered the different CCD mu-
tations found in the NH
 
2
 
-terminal region of RyR1 into a rabbit RyR1 cDNA (R164C, I404M, Y523S, R2163H, and
R2435H) and characterized the functional effects of these mutations after expression in myotubes derived from
RyR1-knockout (dyspedic) mice. Resting Ca
 
2
 
 
 
 levels were elevated in dyspedic myotubes expressing four of these
 
mutants (Y523S 
 
 
 
 R2163H 
 
 
 
 R2435H R164C 
 
 
 
 I404M RyR1). A similar rank order was also found for the degree
of SR Ca
 
2
 
 
 
 depletion assessed using maximal concentrations of caffeine (10 mM) or cyclopiazonic acid (CPA, 30
 
 
 
M). Although all of the CCD mutants fully restored L-current density, voltage-gated SR Ca
 
2
 
 
 
 release was smaller
and activated at more negative potentials for myotubes expressing the NH
 
2
 
-terminal CCD mutations. The shift in
the voltage dependence of SR Ca
 
2
 
 
 
 release correlated strongly with changes in resting Ca
 
2
 
 
 
, SR Ca
 
2
 
 
 
 store deple-
tion, and peak voltage–gated release, indicating that increased release channel activity at negative membrane po-
tentials promotes SR Ca
 
2
 
 
 
 leak. Coexpression of wild-type and Y523S RyR1 proteins in dyspedic myotubes resulted
in release channels that exhibited an intermediate degree of SR Ca
 
2
 
 
 
 leak. These results demonstrate that the
NH
 
2
 
-terminal CCD mutants enhance release channel sensitivity to activation by voltage in a manner that leads to
increased SR Ca
 
2
 
 
 
 leak, store depletion, and a reduction in voltage-gated Ca
 
2
 
 
 
 release. Two fundamentally distinct
cellular mechanisms (leaky channels and EC uncoupling) are proposed to explain how altered release channel
function caused by different mutations in RyR1 could result in muscle weakness in CCD.
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INTRODUCTION
 
Rapid elevations of intracellular Ca
 
2
 
 
 
 in skeletal muscle
are controlled by a unique, bidirectional signaling inter-
action between L-type Ca
 
2
 
 
 
 channels (L-channels* or
DHPRs) in the sarcolemma and Ca
 
2
 
 
 
 release channels
(ryanodine receptors or RyR1s) of the SR. During skele-
tal muscle excitation-contraction (EC) coupling, action
potentials in the sarcolemma induce conformational
 
changes in dihydropyridine receptors
 
 (
 
DHPRs) that rap-
idly trigger the opening of nearby SR Ca
 
2
 
 
 
 release chan-
nels (orthograde coupling; Melzer et al., 1995). Inter-
estingly, DHPR channel activity is strongly dependent
on the presence of RyR1 (retrograde coupling), thus
demonstrating the reciprocal nature of the DHPR–
RyR1 interaction (Nakai et al., 1996; Grabner et al.,
1999; Avila and Dirksen, 2000). The central roles of
DHPR and RyR1 proteins in skeletal muscle Ca
 
2
 
 
 
 ho-
meostasis is emphasized by the fact that point mutations
in both of these proteins account for several different
congenital human muscle diseases (e.g., hypokalemic
periodic paralysis, malignant hyperthermia, and central
core disease [CCD]; Lorenzon and Beam, 2000).
 
CCD, ﬁrst described by Shy and Magee (1956), is a
 
human autosomal dominant, nonprogressive myopathy
characterized by hypotonia and proximal muscle weak-
ness in infancy. Muscle weakness of the lower extremities
leading to delayed attainment of motor skill milestones
is the most common complication. However, the symp-
toms can vary from mild to severe with a marked diver-
sity in skeletal muscle involvement. Diagnosis of CCD is
conﬁrmed by histological examination of muscle biopsy
tissue in which type 1 ﬁbers exhibit amorphous central
areas (cores) that lack both mitochondria and oxidative
enzyme activity (Dubowitz and Pearse, 1960). Electron
microscopic analysis of central cores shows disintegra-
tion of the contractile apparatus and alterations in the
 
structure and amount of SR and transverse tubule
(t-tubule) membranes (Hayashi et al., 1989). Less dra-
matic abnormalities are observed in the noncore or pe-
 
ripheral regions of the muscle ﬁbers. Finally, CCD patients
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are typically susceptible to episodes of malignant hyper-
thermia (MH), a pharmacogenetic syndrome in which
individuals respond to potent inhalation anesthetics
(e.g., halothane) and depolarizing skeletal muscle relax-
ants (e.g., succinylcholine) with high fever, skeletal mus-
cle rigidity, hypermetabolism, lactic acidosis, hypoxia,
and tachycardia (Jurkat-Rott et al., 2000) 
CCD and MH are localized to human chromosome
19q13.1, which includes the locus of RyR1 (MacKenzie
et al., 1990; Kausch et al., 1991). So far, a total of 26 dif-
ferent point mutations in RyR1 have been shown to ac-
count for MH, nine of which are also associated with
CCD (McCarthy et al., 2000). A single point mutation in
RyR1 (R615C) accounts for all cases of porcine MH,
suggesting its origin in a founder animal (Fujii et al.,
1991). All of the identiﬁed MH and CCD point muta-
tions in RyR1 occur within three relatively restricted re-
gions of the RyR1 protein: MH/CCD region 1 (residues
35–614), MH/CCD region 2 (residues 2,129–2,458),
and MH/CCD region 3 (COOH-terminal region, in-
cluding residues 4,637–4,898). The MH and CCD muta-
tions in RyR1 are hypothesized to lead to the formation
of SR Ca
 
2
 
 
 
 release channels that exhibit varying degrees
of Ca
 
2
 
 
 
 leak (MacLennan, 1992; Zhang et al., 1993; Mac-
Lennan and Phillips, 1995). According to this hypothe-
sis, MH mutations result in release channels that exhibit
lesser degrees of Ca
 
2
 
 
 
 leak, whereas the CCD mutations
result in release channels that are severely leaky to Ca
 
2
 
 
 
,
which leads to Ca
 
2
 
 
 
-induced alterations and damage to
the core of the muscle ﬁber. Support for this hypothesis
comes from the observation that resting Ca
 
2
 
 
 
 is elevated
and intracellular Ca
 
2
 
 
 
 stores are depleted in HEK-293
cells transfected with MH and CCD mutant RyR1 pro-
teins (Tong et al., 1997, 1999; Lynch et al., 1999; Mon-
nier et al., 2000). 
However, the physiological effects of the CCD muta-
tions in RyR1 on EC coupling and intracellular Ca
 
2
 
 
 
homeostasis in intact skeletal muscle have yet to be sys-
tematically studied. As a step toward this goal, we re-
cently evaluated the functional properties of a CCD
mutation in MH/CCD region 3 (I4897T) after expres-
sion in skeletal myotubes derived from “RyR1-knock-
out” (dyspedic) mice (Nakai et al., 1996). Contrary to
the results obtained with the same mutation expressed
in HEK 293 cells (Lynch et al., 1999), we found that
I4897T-containing release channels reconstituted in
dyspedic myotubes are not abnormally leaky to Ca
 
2
 
 
 
,
but rather, release SR Ca
 
2
 
 
 
 ineffectively in response
to sarcolemmal depolarization (termed “EC uncoupling”;
Avila et al., 2001a). Thus, functional analysis of each of
the CCD mutants operating within dyspedic myotubes
is advantageous since: dyspedic myotubes express other
proteins (Buck et al., 1997) critical for the modulation
of release channel function (e.g., calmodulin, FK-506
binding protein, triadin, calsequestrin, and DHPR),
 
several of which are relatively muscle speciﬁc; the effects
of the mutations on the orthograde and retrograde sig-
nals of EC coupling can only be studied in the context
of muscle expression systems; and the inﬂuence of en-
dogenous compensatory mechanisms recruited in re-
sponse to the introduction of mutant release channels
should be more accurately reﬂected after reconstitu-
tion in dyspedic myotubes. 
Five amino acid residues (R163, I403, Y522, R2163,
and R2435) account for the six different CCD mutations
in the NH
 
2
 
-terminal or cytoplasmic “foot” region of the
human RyR1 protein (MH/CCD regions 1 and 2; Quane
et al., 1993, 1994; Zhang et al., 1993; Manning et al.,
1998; Barone et al., 1999). The effects of these cytoplas-
mic CCD mutations on release channel activity in skele-
tal muscle have not been determined. Therefore, we
have evaluated the functional consequences (on resting
Ca
 
2
 
 
 
, SR Ca
 
2
 
 
 
 content, and EC coupling) of the NH
 
2
 
-ter-
minal CCD mutations engineered into a rabbit RyR1
cDNA after expression in dyspedic myotubes. 
 
MATERIALS AND METHODS
 
Preparation and cDNA Injections of Dyspedic Myotubes
 
Myotubes were prepared from primary cultures of dyspedic mus-
cle as described previously (Nakai et al., 1996; Avila and Dirksen,
2000). All animal protocols were reviewed and approved by the
University Committee on Animal Resources at the University of
Rochester School of Medicine and Dentistry. Each of the differ-
ent CCD point mutations in RyR1 used in this study (R164C,
I404M, Y523S, R2163H, R2435H, and I4897T) was introduced
into a rabbit RyR1 cDNA using standard two-step site-directed
mutagenesis strategies. Expression of wild-type RyR1 and the dif-
ferent NH
 
2
 
-terminal CCD mutations in RyR1 was achieved by nu-
clear microinjection of cDNAs encoding CD8 (0.2 
 
 
 
g/
 
 
 
l) and
the appropriate expression plasmid (0.5 
 
 
 
g/
 
 
 
l) 4–6 d after ini-
tial planting of myoblasts (Avila et al., 2001b). A 1:1 cDNA mix-
ture (0.25 
 
 
 
g/
 
 
 
l each) was used in experiments of dyspedic myo-
tubes coexpressing RyR1 and Y523S (see Fig. 5). Expressing myo-
tubes were identiﬁed 2–4 d after nuclear microinjection by
incubation with CD8 antibody beads. 
 
Intracellular Ca
 
2
 
 
 
 Measurements in Intact Myotubes 
 
Measurements of resting Ca
 
2
 
 
 
 were obtained in intact, Indo-1
AM–loaded myotubes (Molecular Probes) as described previ-
ously (Avila et al., 2001b). The ratio of ﬂuorescence emission at
405 and 485 (F
 
405
 
/F
 
485
 
) was converted to cytosolic Ca
 
2
 
 
 
 levels us-
ing an in situ calibration approach (Avila et al., 2001b). Relative
changes in global Ca
 
2
 
 
 
 levels were subsequently monitored after
application of rodent Ringer (see 
 
results
 
) containing either 10
mM caffeine (see Fig. 1) or 30 
 
 
 
M cyclopiazonic acid (CPA; see
Fig. 2). Caffeine- and CPA-induced Ca
 
2
 
 
 
 transients were not con-
verted to free Ca
 
2
 
 
 
 since Ca
 
2
 
 
 
 levels above 
 
 
 
150 nM resulted in
contractions that could introduce movement artifacts into the
calibration (Avila et al., 2001b). To resolve rapid elevations in in-
tracellular Ca
 
2
 
 
 
 levels, caffeine was applied through a local, rapid
(response time 
 
 
 
5s) perfusion system (Warner Instrument Cor-
poration). Several myotubes within a single dish could be moni-
tored separately since the perfusion system limits caffeine accu-
mulation in the bath, and responses to multiple applications of
caffeine separated by 
 
 
 
10-min wash intervals were similar. Sim- 
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ple gravity perfusion (
 
 
 
30s for complete solution exchange) was
used to monitor the slower changes in intracellular Ca
 
2
 
 
 
 induced
by application of 30 
 
 
 
M CPA (Avila et al., 2001a). 
 
Simultaneous Measurements of Macroscopic Ca
 
2
 
 
 
 Currents 
and Ca
 
2
 
 
 
 Transients
 
The whole-cell patch-clamp technique was used to simulta-
neously measure voltage-gated L-currents and Ca
 
2
 
 
 
 transients in
expressing myotubes (Avila and Dirksen, 2000; Avila et al.,
2001a,b). Sodium and T-type Ca
 
2
 
 
 
 currents were eliminated us-
ing a standard prepulse protocol consisting of a 1-s depolariza-
tion usually to 
 
 
 
30 mV followed by a 25-ms repolarization to 
 
 
 
50
mV before each test pulse (Avila and Dirksen, 2000). L-currents
were leak subtracted (
 
 
 
P/3) and normalized to cell capacitance
(pA/pF). Peak L-currents were plotted as a function of test po-
tential and ﬁtted according to:
 
(1)
 
where V
 
rev
 
 is the extrapolated reversal potential of the Ca
 
2
 
 
 
 cur-
rent, V
 
m
 
 is the membrane potential during the test pulse, G
 
max
 
 is
the maximum L-channel conductance,   is the voltage for
half activation of G
 
max
 
, and 
 
k
 
G
 
 is a slope factor. Relative changes
in cytosolic Ca
 
2
 
 
 
 in patch-clamp experiments were recorded in
Fluo-3-dialyzed myotubes. Fluorescence traces were analogue-ﬁl-
tered (
 
 
 
 
 
 
 
 0.5 ms) before digitization (10 kHz), and subse-
quently expressed as 
 
 
 
F/F. Amplitudes at the end of each test
pulse were plotted as a function of the membrane potential, and
ﬁtted according to:
 
(2)
 
where (
 
 
 
F/F)
 
max
 
 is the calculated maximal ﬂuorescence change
during the test pulse,   is the midpoint potential, and 
 
k
 
F
 
 is a
slope factor. 
 
Recording Solutions
 
Cytosolic Ca
 
2
 
 
 
 levels were monitored in myotubes bathed in nor-
mal rodent Ringer containing the following (in mM): 145 NaCl,
5 KCl, 2 CaCl
 
2
 
, 1 MgCl
 
2
 
, and 10 HEPES, pH
 
 
 
7.4. For measure-
ments of macroscopic Ca
 
2
 
 
 
 currents and intracellular Ca
 
2
 
 
 
 tran-
sients, the pipette solution contained the following (in mM): 145
cesium aspartate, 10 CsCl, 0.1 Cs
 
2
 
-EGTA, 1.2 MgCl
 
2
 
, 5 Mg-ATP,
0.2 K
 
5
 
-Fluo-3 (Molecular Probes), and 10 HEPES, pH
 
 
 
7.4. In
these experiments, the external solution contained the following
(in mM): 145 TEA-Cl, 10 CaCl
 
2
 
, 0.003 TTX, and 10 HEPES, pH
7.4. Except where noted, all chemical reagents were obtained
from Sigma-Aldrich.
 
RESULTS
 
Effects of CCD Mutations on Resting Ca
 
2
 
 
 
 and 
SR Ca
 
2
 
 
 
 Content
 
Compared with wild-type RyR1, HEK-293 cells express-
ing NH
 
2
 
-terminal CCD mutations in RyR1 exhibited ele-
vated resting Ca
 
2
 
 
 
 levels and a reduction in the Ca2 
content of the ER (Tong et al., 1999). To evaluate the
functional impact of the CCD mutations on Ca2  dy-
namics in skeletal muscle, we expressed wild-type RyR1
and ﬁve of the different NH2-terminal CCD mutations
IG max Vm Vrev – () 1 exp VG12 ⁄ Vm – () kG ⁄ [] + {} ⁄ , ⋅ =
VG12 ⁄
F ∆ F ⁄ F ∆ F ⁄ () max 1 exp VF12 ⁄ Vm – () kF ⁄ [] + {} , ⁄ =
VF12 ⁄
in RyR1 (I404M, R164C, R2435H, R2163H, and Y523S)
in dyspedic myotubes (which lack RyR1 proteins). Rest-
ing Ca2  and caffeine responses were evaluated in intact
Indo-1 AM–loaded myotubes (Fig. 1). RyR1- and I4897T-
expressing dyspedic myotubes exhibited similar resting
Ca2  levels, which were higher than that of uninjected
myotubes (Fig. 1 B; Avila et al., 2001a). Interestingly,
dyspedic myotubes expressing four of the ﬁve different
NH2-terminal CCD mutations in RyR1 (R164C, R2435H,
R2163H, and Y523S, but not I404M) exhibited signiﬁ-
cant (P   0.05) elevations in resting Ca2  (Fig. 1, A and
B) according to the following rank order: Y523S  
R2163H   R2435H   R164C   I404M   RyR1. For
clarity, the data for each of the different constructs in
Figs. 1–4 are presented using this rank order. Under
control conditions, some of the myotubes expressing ei-
ther wild-type RyR1 or the different NH2-terminal CCD
mutants exhibited spontaneous intracellular Ca2  tran-
sients that varied in frequency, amplitude, and duration
(Fig. 1 A). The percentages of myotubes exhibiting
spontaneous Ca2  oscillations during the ﬁrst  60 s of
recording were the following: 33% (14/43), 25% (5/
20), 54% (15/28), 65% (13/20), 54% (15/28), and
10% (2/20), for RyR1-, I404M-, R164C-, R2435H-,
R2163H-, and Y523S-expressing myotubes, respectively.
In contrast, none of the I4897T-expressing myotubes
(0/16) or uninjected dyspedic myotubes (0/33) studied
exhibited spontaneous Ca2  oscillations. In general,
resting Ca2  levels were elevated and Ca2  oscillations
were smaller and of higher frequency in the NH2-termi-
nal CCD-expressing myotubes (Figs. 1 A and 2 A). How-
ever, since the frequency and magnitude of Ca2  oscilla-
tions could be inﬂuenced by differences in spontaneous
electrical activity, the patterns of these Ca2  oscillations
for the different constructs were not characterized in
greater detail. Interestingly, a similar pattern of Ca2  os-
cillations were also observed at the holding potential
( 80 mV) in whole-cell patch-clamp experiments (data
not shown), suggesting that increased spontaneous re-
lease does not solely arise from elevated intracellular
Ca2  levels or membrane depolarization.
The trend for the different CCD mutations in RyR1 to
cause an elevation in resting Ca2  as well as smaller am-
plitude Ca2  oscillations is consistent with the notion
that the CCD mutations lead to the expression of leaky
SR Ca2  release channels. Since leaky SR Ca2  release
channels may result in SR Ca2  store depletion we evalu-
ated SR Ca2  content after application of a maximal
concentration of caffeine (10 mM; Fig. 1 A). Dyspedic
myotubes expressing four of the ﬁve different NH2-ter-
minal CCD mutant RyR1 proteins (R164C, R2435H,
R2163H, and Y523S) exhibited a signiﬁcantly smaller re-
sponse to caffeine compared with that of wild-type RyR1
(P   0.05; Fig. 1). Interestingly, repetitive Ca2  oscilla-
tions were typically observed throughout the caffeine280 CCD Mutations Alter Release Channel Function
application in 90% (17/19) of RyR1-expressing myo-
tubes. However, repetitive caffeine-induced Ca2  oscil-
lations were less frequent: 43% (6/14), 31% (4/13),
43% (3/7), 0% (0/11), and 0% (0/8) for I404M,
R164C, R2435H, R2163H, and Y523S, respectively. A
reduction in repetitive Ca2  oscillations could arise
from differences in the caffeine-induced plateau Ca2 
level or reductions in either SR Ca2  content and/or
release channel inhibition by high Ca2  (Fill et al.,
1990). 
The data presented in Fig. 1 suggest that expression
of NH2-terminal CCD mutant RyR1 proteins in dys-
pedic myotubes results in a signiﬁcant depletion of SR
Ca2  stores. This idea was further tested by evaluating
SR Ca2  content using a method to release Ca2  by a
mechanism that is independent of RyR1 activation
Figure 1.  Intact dyspedic myotubes expressing NH2-terminal CCD mutants exhibit higher resting Ca2  levels and a reduced maximal
caffeine-induced Ca2  release. (A) Representative caffeine-induced Ca2  responses (10 mM caffeine, black bars) in Indo-1 AM–loaded dys-
pedic myotubes expressing wild-type RyR1, I404M, R164C, R2435H, R2163H, or Y523S. The abscissa for each panel corresponds to 5 min.
(B) Average resting Ca2  levels in dyspedic myotubes expressing RyR1 and the different CCD mutations. Unstimulated Indo-1 ﬂuores-
cence ratios were converted to resting Ca2  levels using an in situ calibration approach (Avila et al., 2001a). (C) Average maximal caffeine-
induced Ca2  release (  Ratio   Rcaffeine   Rbaseline). Asterisks indicate signiﬁcant differences (P   0.05) compared with RyR1. 281 Avila and Dirksen
(Fig. 2). For these experiments, luminal SR Ca2  stores
were assessed after treatment with CPA, an agent that
increases cytosolic Ca2  by reversibly inhibiting SR Ca2 -
ATPase pumps, and thereby prevents the reuptake of
Ca2  lost through passive leak pathways. Application
of CPA (Fig. 2, 30  M, black bars) induced similar in-
creases in cytosolic Ca2  in intact dyspedic myotubes
either expressing RyR1 or I404M. However, dyspedic
myotubes expressing the other NH2-terminal CCD
mutants exhibited signiﬁcantly smaller elevations in
cytosolic Ca2  after application of CPA, which is con-
sistent with these mutants reducing luminal SR Ca2 
levels. Although caffeine fails to activate Ca2  release
in I4897T-expressing myotubes (Fig. 1 C), these myo-
tubes exhibit a resting Ca2  level and CPA-sensitive
Ca2  store comparable to that of RyR1-expressing
myotubes (Figs. 1 A and 2 B; Avila et al., 2001a). These
results indicate that I4897T-containing release chan-
nels do not result in the formation of overactive, or
leaky Ca2  release channels, but rather release Ca2 
inefﬁciently after activation (by caffeine or voltage).
Effects on Retrograde and Orthograde Signals of EC Coupling
EC coupling in skeletal muscle involves a unique bidi-
rectional signaling interaction between RyR1s and DH-
PRs. Accordingly, while DHPRs trigger the activation of
RyR1 proteins in response to a sarcolemmal depolariza-
tion (orthograde coupling), the functional activity of
the DHPR (retrograde coupling) is in turn strongly in-
ﬂuenced by the presence of RyR1 (Nakai et al., 1996;
Grabner et al., 1999; Avila and Dirksen, 2000). We used
the whole-cell patch-clamp technique in conjunction
with a Ca2 -sensitive dye to evaluate the effects of the
different NH2-terminal CCD mutations in RyR1 on the
retrograde (Fig. 3) and orthograde (Fig. 4) signals of
skeletal muscle EC coupling. Uninjected dyspedic myo-
tubes exhibit a very low L-current density and com-
pletely lack voltage-gated SR Ca2  release. Reintroduc-
tion of RyR1 proteins restores both robust L-currents
and voltage-gated SR Ca2  release (Nakai et al., 1996).
Dyspedic myotubes expressing each of the different
NH2-terminal CCD mutant RyR1s exhibited L-currents
Figure 2.  Intact dyspedic myotubes ex-
pressing NH2-terminal CCD mutants ex-
hibit reduced CPA-induced Ca2  release.
(A) Representative CPA-induced Ca2  re-
sponses (30  M, black bars) in Indo-1 AM–
loaded dyspedic myotubes expressing wild-
type RyR1, I404M, R164C, R2435H,
R2163H, or Y523S. For comparison, ﬂuo-
rescence ratios are aligned to their respec-
tive baseline levels (dotted lines). (B) Aver-
age steady-state CPA-induced Ca2  release
(  Ratio   RCPA   Rbaseline) measured 2–3
min after the initial application of CPA. As-
terisks indicate signiﬁcant differences (P  
0.05) compared with RyR-1. 282 CCD Mutations Alter Release Channel Function
of similar magnitude, kinetics, and voltage dependence
as those recorded from wild-type RyR1-expressing dys-
pedic myotubes (Fig. 3). These results indicate that
each of the mutants are synthesized and targeted to sar-
colemmal–SR junctions and are able to functionally in-
teract with DHPRs present within the junctions. More-
over, the results indicate that none of the NH2-terminal
CCD mutations in RyR1 markedly inﬂuence retrograde
coupling between DHPR and RyR1 proteins.
Although the NH2-terminal CCD mutations in RyR1
did not alter retrograde coupling, signiﬁcant effects on
orthograde coupling were observed (Fig. 4). Fig. 4 A il-
lustrates representative voltage-gated Ca2  transients
recorded under whole-cell voltage clamp for dyspedic
myotubes expressing wild-type RyR1 and each of the
different CCD mutant RyR1 proteins. In general, volt-
age-gated Ca2  transients attributable to the NH2-termi-
nal CCD mutant release channels were smaller and ac-
tivated at more negative potentials than Ca2  transients
arising from wild-type RyR1. This can best be appreci-
ated by comparing voltage-gated Ca2  transients arising
from RyR1 (Fig. 4 A, upper left) and Y523S (Fig. 4 A,
lower right). Even though the Y523S transients illus-
trated in Fig. 4 A were the largest we recorded (n  
11), the maximal transient (at  70 mV) for this con-
struct was still more than three times smaller than that
of wild-type RyR1. In addition, the threshold for activa-
tion of Y523S-expressing myotubes was  40 mV more
hyperpolarized than that of RyR1-expressing myotubes.
The other NH2-terminal CCD mutations in RyR1 also
resulted in reductions in maximal voltage-gated Ca2 
release and a negative shift in the voltage dependence
of release, although to a lesser extent that Y523S. Thus,
although the largest maximal voltage-gated Ca2  tran-
Figure 3.  The NH2-terminal CCD mutants fully restore retrograde coupling. (A) Representative whole-cell L-currents recorded in re-
sponse to 30-ms depolarizing pulses to the indicated membrane potentials (left). (B) Average peak I-V curves for dyspedic myotubes ex-
pressing wild-type RyR1 (n   20), I404M (n   7), R164C (n   10), R2435H (n   8), R2163H (n   6), or Y523S (n   11). The average val-
ues ( SEM) for the parameters obtained by ﬁtting each myotube within a group separately to Eq. 1 are given in Table I (I–V data). The
solid lines through the data were generated using Eq. 1 and the corresponding parameters given in Table I ([dashed line] RyR1 and [con-
tinuous line] CCD mutants). 283 Avila and Dirksen
sients were recorded from wild-type RyR1-expressing
myotubes, the NH2-terminal CCD mutants actually ex-
hibited larger Ca2  transients at threshold potentials.
For example, the Ca2  transient amplitudes at  10 mV
were the following (in  F/F): 0.04   0.02, 0.11   0.05,
0.72   0.19, 0.33   0.10, 1.18   0.45, and 0.27   0.15,
for RyR1, I404M, R164C, R2435H, R2163H, and
Y523S, respectively. To provide a more quantitative de-
scription of this observation, Boltzmann ﬁts to the volt-
age dependence of SR Ca2  release for each construct
were used to determine the maximal change in ﬂuo-
rescence ( F/Fmax), the half-maximal activation volt-
age ( ), and voltage sensitivity (kF; Fig. 4 B). This
analysis revealed that each of the NH2-terminal CCD
mutations in RyR1 caused a signiﬁcant negative shift in
 without changing kF (Table I). The various de-
grees of hyperpolarizing shift in the activation of volt-
age-gated SR Ca2  release caused by the different NH2-
terminal CCD mutations in RyR1 are best appreciated
by comparing the normalized voltage dependence of
VF12 ⁄
VF12 ⁄
Figure 4.  The NH2-terminal CCD mutants increase SR Ca2  release channel sensitivity to activation by voltage and reduce maximal volt-
age-gated SR Ca2  release. (A) Intracellular Ca2  transients ( F/F) elicited by 30-ms test pulses to the indicated potentials (left). (B) Aver-
age voltage dependence of peak intracellular Ca2  transients as recorded in A. The average values ( SEM) for the parameters obtained by
ﬁtting each myotube within a group separately to Eq. 2 are given in Table I ( F/F -V data). The solid lines through the data were gener-
ated using Eq. 2 and the corresponding parameters given in Table I ([dashed line] RyR1 and [continuous lines] CCD mutants). (C) The
 F/F-V data and curves in B were normalized to their respective maximal value (( F/F)max) ([dashed line] RyR-1 and [continuous lines]
CCD mutants). The decline in the magnitude of the Y523S Ca2  transients at potentials greater than  30 mV arises from a reduction in
L-current magnitude at these potentials.284 CCD Mutations Alter Release Channel Function
release for each mutant to that of wild-type RyR1 (Fig.
4 C). 
Since individuals with CCD are typically heterozygous
for the causative RyR1 mutation, we also investigated
the effects of coexpression of RyR1 and Y523S in dys-
pedic myotubes (Fig. 5). We evaluated the impact of
RyR1/Y523S coexpression since this mutation resulted
in the most severe disruption in Ca2  homeostasis
(Figs. 1 and 2) and voltage-gated SR Ca2  release (Fig.
4). Not surprisingly, RyR1/Y523S-expressing dyspedic
myotubes displayed L-currents with a similar magni-
tude, kinetics, and voltage dependence as those re-
corded from homozygous RyR1-expressing myotubes
(Fig. 5, A and B, and Table I). However, RyR1/Y523S-
expressing myotubes exhibited the following: only a
moderate elevation in resting Ca2  (for RyR1, 49   7.8
nM, n   43; for RyR1/Y523S, 94   11 nM, n   23); and
voltage-gated Ca2  transients that were intermediate in
magnitude and voltage dependence to those arising
from homozygous expression of either construct (Fig.
5, C and D). The effects on voltage-gated Ca2  release
are qualitatively similar to those observed after coex-
pression of RyR1/I4897T (Avila et al., 2001a). Thus, al-
though voltage-gated SR Ca2  release is reduced after
TABLE I
Parameters of Fitted I-V and  F/F-V Curves
I-V Data  F/F-V Data
n Gmax kG vrev ( F/F)max kF
nS/nF mV mV mV mV mV
RyR-1 20 126   9.1 17.7   1.0 6.1   0.1 77   1.4 2.8   0.3  9.5   1.1 5.4   0.4
1404M 7 126   20 19.8   2.8 6.8   0.3 80   1.8 2.7   0.6  5.0   2.4a 5.2   0.8
R164C 10 125   11 20.5   1.7 7.2   0.3a 75   3.0 2.0   0.4  5.6   2.8a 6.0   0.5
R2435H 8 123   12 23.2   1.5a 8.1   0.2a 80   4.1 1.5   0.3a  1.0   2.6a 6.0   0.8
R2163H 6 153   16 22.1   2.2 7.5   0.4a 74   6.9 2.3   0.5  9.4   2.2a 5.0   0.3
Y523S 11 119   16 18.1   1.4 8.5   0.2a 85   2.2a 0.3   0.1a  21   6.1a 5.1   1.1
RYR-1/Y523S 13 139   14 15.4   1.0 7.4   0.2a 72   2.8 1.3   0.3a  7.5   2.6a 6.4   0.7
aCompared to RYR-1 P   0.05.
VG12 ⁄ VF12 ⁄
Figure 5.  Coexpression of
the wild-type RyR1 and Y523S
causes an intermediate shift in
 and a moderate reduc-
tion in voltage-gated SR Ca2 
release. (A) L-currents (left)
and intracellular Ca2  tran-
sients (right) obtained from a
representative RyR1/Y523S-
expressing dyspedic myo-
tube. Average voltage depen-
dence of maximal L-currents
(B) and Ca2  transients (C) in
RyR-1/Y523S-expressing myo-
tubes (n   13). The continu-
ous lines were calculated us-
ing Eq. 1 (B) and Eq. 2 (C)
from the values reported in
Table I.   The average I-V and
F-V curves for RyR1- and
Y523S-expressing myotubes
are illustrated for comparison
(dashed lines). (D) The  F/
F-V curves in C were normal-
ized to their respective maxi-
mal value ( F/F)max. 
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coexpression of both Y523S and I4897T, the mutations
differ with regard to their effects on resting   Ca2 
and SR Ca2  content (Avila et al., 2001a). 
Correlation between Effects on Ca2  Dynamics and Release 
Channel Sensitivity to Activation by Voltage ( )
To test whether changes in release channel sensitivity
to voltage (i.e.,  ) might account for the observed
changes in resting Ca2 , SR Ca2  content, and maximal
voltage-gated Ca2  release, a linear correlation analysis
was conducted for the data obtained from dyspedic
myotubes expressing RyR1 and each of the NH2-terminal
CCD mutations (Fig. 6). The elevation in resting Ca2 
correlated strongly with the degree of shift in 
(Fig. 6 A, r   0.97, P   0.05). In addition, myotube re-
sponsiveness to maximal concentrations of both caf-
feine (Fig. 6 B, r   0.97, P   0.05) and CPA (Fig. 6 C, r  
0.80, P   0.05), two different means of assessing SR
Ca2  content, also correlated well with  . Finally,
the degree of reduction in maximal voltage-gated SR
Ca2  release also correlated with release channel sensi-
tivity to activation by voltage (Fig. 6 D, r   0.86, P  
0.05) across the different RyR1 constructs. Although
these correlational analyses fall short of establishing
causation, the results suggest that increased release
VF12 ⁄
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channel sensitivity to activation by voltage contributes
to the enhanced SR Ca2  leak, Ca2  store depletion,
and a reduction in Ca2  released during EC coupling
in dyspedic myotubes expressing the different NH2-ter-
minal CCD mutations in RyR1.
DISCUSSION
Functional Impact of NH2-terminal CCD Mutations on RyR1 
Activity in Dyspedic Myotubes 
Our experiments are the ﬁrst to characterize the rela-
tive effects of the different NH2-terminal CCD muta-
tions in RyR1 on release channel activity operating
within a skeletal muscle environment. The results indi-
cate that dyspedic myotubes expressing the different
NH2-terminal CCD mutations in RyR1 exhibit different
degrees of SR Ca2  leak as judged by the presence of
parallel, but opposing, changes in resting Ca2  and SR
Ca2  content. None of the NH2-terminal CCD mutants
markedly altered L-current magnitude, kinetics, or volt-
age dependence (Fig. 3). However, the NH2-terminal
CCD mutations reduced maximal voltage-gated Ca2 
release and caused a negative shift in   (Fig. 4), in-
dicating that the CCD mutations in RyR1 selectively al-
ter the orthograde signal of skeletal muscle EC cou-
VF12 ⁄
Figure 6.  The degree of altered re-
lease channel activity for the different
NH2-terminal CCD mutations in RyR1
correlates with a hyperpolarizing shift
in  . Average resting Ca2  levels
(A), maximal caffeine response (B),
maximal CPA response (C), and maxi-
mal voltage-gated Ca2  release (D) are
plotted as a function of   for RyR1
and the different NH2-terminal CCD
mutants. Symbols represent RyR1
(closed circle), R164C (open dia-
mond), I404M (open triangle), Y523S
(open circle), R2163H (open square),
R2435H (inverted open triangle), and
RyR1/Y523S (dotted closed circle).
VF12 ⁄
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pling. The degree of reduction in voltage-gated release
correlated well with the shift in   across the differ-
ent NH2-terminal CCD mutations in RyR1. These data
are the ﬁrst to suggest that increased release channel
activity at negative membrane potentials results in an
elevation in resting Ca2  and a partial reduction in SR
VF12 ⁄
Ca2  content. In spite of these correlations, we should
point out that our experiments have not deﬁnitively
demonstrated that the observed increased sensitivity to
activation by voltage (i.e., negative shift in  ) ob-
served for the NH2-terminal CCD mutants is directly re-
sponsible for an increase in SR Ca2  leak.
VF12 ⁄
Figure 7.  Schematic representation for alterations in Ca2  homeostasis and EC coupling in dyspedic myotubes expressing normal (left,
RyR1), leaky (middle, Y523S), and EC uncoupled (right, I4897T) SR Ca2  release channels. Each model is based on the 5-state reaction
scheme for coupled DHPRs and RyR1s (Dietze et al., 2000). A thin black line connecting DHPR (black channels) and RyR1 proteins
(white and gray channels) is used to represent mechanical coupling. The number of Ca2  symbols represents relative myoplasmic and lu-
minal SR Ca2  levels. In each scheme, L-channels are assumed to exist in one of three distinct states governed by two voltage-dependent
transitions (V12 and V23): (1) resting (closed), (2) preactive (closed), and (3) open (open). In each of these states, coupled SR Ca2  release
channels can exist in either a closed (states 1–3) or open conﬁguration (states 4 and 5). A reduction in the voltage-independent equilib-
rium constant (K) for the release channel open-closed reaction causes a selective negative shift in   without an alteration in  . The
selective, but variable shifts in   produced by the different NH2-terminal CCD mutations in RyR1, could arise from different degrees of
reductions in K in the model for Y523S. Increased release channel activity at negative potentials could result in SR Ca2  leak and the subse-
quent depletion of SR Ca2  stores. Our previous results demonstrated that I4897T-expressing myotubes lack voltage-gated SR Ca2  release
in the absence of a change in either resting Ca2  levels or SR Ca2  content (Avila et al., 2001a). However, the I4897T mutation apparently
does not alter K, since the value of   was similar for dyspedic myotubes expressing RyR1 alone and both RyR1 and I4897T. Thus, the
I4897T mutation may result in release channels that conduct Ca2  poorly after activation (depicted as gray release channels). Both cellular
mechanisms (“leaky” and “uncoupled” SR Ca2  release channels) would be expected to result in muscle weakness as a consequence of re-
duced voltage-gated SR Ca2  release. Disorganization of the contractile proteins and a reduction in energy supply within the core regions
are also likely to contribute to muscle weakness in CCD (Loke and MacLennan, 1998; MacLennan and Phillips, 1995). 
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Two Distinct Cellular Mechanisms for Muscle 
Weakness in CCD
Since our results obtained with the NH2-terminal CCD
mutants are in contrast to those obtained after expres-
sion of I4897T (Avila et al., 2001a), we propose two dis-
tinct cellular mechanisms to account for muscle weak-
ness in CCD (Fig. 7). The models presented in Fig. 7 are
based on the 5-state kinetic model that was recently
used to account for the voltage dependence of both
L-currents and SR Ca2  release in porcine skeletal myo-
tubes homozygously expressing the R615C MH muta-
tion (Dietze et al., 2000). In this model, the equilibrium
constant (Fig. 7, “K”) governing a voltage-independent
transition of the release channel is linked to ligand-
modulated gating of RyR1, such that triggering agents
(e.g., caffeine, halothane, and voltage sensor) promote
release channel opening by reducing the value of K
(i.e., stabilizing the open state of the release channel).
Accordingly, an eightfold reduction in K quantitatively
accounts for the selective hyperpolarizing shift in 
observed in porcine myotubes (Dietze et al., 2000). The
beauty of this model is that alterations in a single volt-
age-independent equilibrium constant occurs indepen-
dent of the precise molecular mechanism by which the
DHPR and RyR1 are coupled. Thus, mutations in vastly
different regions of RyR1 that exert different degrees of
inﬂuence on K would result in variable, but selective, al-
terations in  . Our ﬁnding of variable shifts in 
(ranging from 5 to 31 mV) caused by the NH2-terminal
CCD mutations in RyR1 could, therefore, arise from
variable reductions in the value of K.
We propose two fundamentally distinct cellular mech-
anisms (leaky channels and EC uncoupling) to explain
how altered SR Ca2  release channel activity caused by
different mutations in RyR1 may result in muscle weak-
ness in CCD (Fig. 7). The three basic schemes pre-
sented in Fig. 7 are based on our results obtained from
expression of RyR1, Y523S, and I4898T in dyspedic
myotubes and are based on the 5-state kinetic model of
DHPR-RyR1 coupled gating (Dietze et al., 2000). Be-
cause RyR1 channel opening is coupled to the voltage
dependence of L-channel opening in this model,
changes in the value of the voltage-independent equi-
librium constant K result in a selective shift of   for
Ca2  release without signiﬁcantly altering the voltage
dependence of L-channel opening. Thus, our ﬁnding
of a selective shift in   with expression of Y523S
mutation in RyR1 (as well as R2163H, RyR1/Y523S,
R164C, R2435H, and I404M) in dyspedic myotubes can
also be explained by a reduction in K. The increased
sensitivity of Y523S-containing release channels to acti-
vation at negative voltages should result in a partial de-
pletion of the SR Ca2  store. If store content is reduced
enough, SR Ca2  release elicited by a single action po-
tential would be smaller than usual, thus, resulting in
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muscle weakness. Coexpression of Y523S with RyR1 re-
sulted in an intermediate shift in  , a more moder-
ate reduction in peak voltage-gated SR Ca2  release,
and a resting Ca2  level that was more than RyR1 but
less than Y523S. Thus, similar to our previous ﬁndings
regarding I4897T, the Y523S mutation in RyR1 exerts a
dominant negative action on the activity of the result-
ing SR Ca2  release channels, which is consistent with
the autosomal dominant pattern of inheritance of this
human myopathy (Isaacs et al., 1975). 
We have previously reported that expression in dys-
pedic myotubes of release channels harboring the
I4898T CCD mutation do not function as leaky SR Ca2 
release channels, but rather reﬂect a functional uncou-
pling of sarcolemmal excitation from SR Ca2  release
(EC uncoupling) (Avila et al., 2001a). This assertion
was based on the observation that I4897T-expressing
dyspedic myotubes lack voltage-gated SR Ca2  release
(orthograde coupling) in spite of the presence of nor-
mal resting intracellular Ca2  levels, CPA-responsive-
ness, and DHPR channel activity (retrograde cou-
pling). Although coexpression of I4897T and RyR1
only partially restored orthograde coupling, the 
values of RyR1- and RyR1/I4897T-expressing dyspedic
myotubes did not differ signiﬁcantly (Avila et al., 2001a).
Taken together, these data indicate that the effects of
the I4897T CCD mutation cannot be described by a
simple reduction in  , and thus, likely involves a
fundamentally distinct mechanism than that of the
NH2-terminal CCD mutations. One possibility is that
the lack of voltage-gated Ca2  release after homozygous
expression of I4897T could arise from a selective dis-
ruption in orthograde coupling, such that the transi-
tion governed by K becomes essentially nonpermissible
(i.e., K approaches inﬁnity; not depicted in Fig. 7). A
reduction in the maximal voltage-gated Ca2  transient
occurring in the absence of a change in   after
RyR1/I4897T coexpression could arise from certain
heteromeric release channel combinations (e.g., con-
sisting predominantly of RyR1) that undergo the transi-
tion governed by K normally, whereas other combina-
tions (e.g., consisting predominantly of I4897T) almost
never undergo this transition. Alternatively, the I4897T
mutation may drastically alter release channel perme-
ation and/or gating in such a way that Ca2  ﬂux
through activated channels is severely compromised
(Fig. 7 C, shaded release channels). Thus, release chan-
nels comprised of I4897T subunits may undergo the
voltage-independent activating transition governed by
K normally, but Ca2  may only conduct poorly through
activated I4897T release channels. Recent ﬁndings that
the I4897T residue contributes to a conserved RyR
pore-forming sequence (Balshaw et al., 1999; Zhao et
al., 1999; Gao et al., 2000) and that conservative muta-
tions I4897 result in marked reductions in single-chan-
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nel conductance, activation by Ca2 , and Ca2  perme-
ation (Gao et al., 2000) supports the latter interpreta-
tion. In this case, heteromeric release channels that
permit intermediate degrees of overall Ca2  perme-
ation could explain the partial restoration of release
channel activity after coexpression of RyR1 and I4897T
in dyspedic myotubes. Thus, we propose two parallel
but converging mechanisms to account for muscle weak-
ness caused by NH2- and COOH-terminal (I4897T) CCD
mutations in RyR1 (Fig. 7). Clearly, it will be important
for future work to determine whether newly identiﬁed
CCD mutations in RyR1 expressed in dyspedic myo-
tubes also result in “leaky” or “EC uncoupled” SR Ca2 
release channels. 
Comparison of Results with Previous Reports
Due to the presence of the porcine model for MH, the
functional effects of the R615C MH mutation in RyR1
has been the most thoroughly characterized of the dif-
ferent disease mutations in RyR1 (for reviews see Mick-
elson and Louis, 1996; Loke and MacLennan, 1998; Jur-
kat-Rott et al., 2000; McCarthy et al., 2000). In skeletal
muscle bundles and myotubes obtained from MH pigs,
contractions exhibit enhanced sensitivity to activation
via both caffeine and sarcolemmal depolarization (Gal-
lant and Lentz, 1992; Gallant and Jordan, 1996). The
increased contractile sensitivity to depolarization arises
from a hyperpolarizing shift in the voltage dependence
of SR Ca2  release (Dietze et al., 2000) that occurs in
the absence of an effect on the magnitude or voltage
dependence of L-currents (Dietze et al., 2000; Gallant
et al., 1996; Gallant and Jordan, 1996). These abnor-
malities, which may be potentiated by inhalation anes-
thetics and depolarizing skeletal muscle relaxants,
would be anticipated to result in supersensitive or over-
active SR Ca2  release channels. Our results are the
ﬁrst to demonstrate that the NH2-terminal CCD muta-
tions in RyR1 also shift   without markedly altering
the voltage dependence of L-channel activation.
Heterologous expression of MH and CCD mutations
in nonmuscle cells has been an alternate approach used
to compare the functional properties of mutant release
channels (Treves et al., 1994; Lynch et al., 1999; Tong et
al., 1997, 1999; Monnier et al., 2000). The studies of
Tong et al. (1997, 1999) represent the most thorough
comparison of the functional impact of the different
MH and CCD mutations in RyR1 evaluated in the con-
text of a single genetic background. In these studies,
resting Ca2  levels, Ca2  content of the ER, and release
channel sensitivity to caffeine and halothane were mon-
itored in HEK-293 cells expressing 15 of the different
MH and CCD mutations in RyR1. These studies found
that the MH and CCD mutant RyR1 proteins exhibited
enhanced sensitivity to caffeine and halothane (Tong et
al., 1997), as well as variable degrees of both store deple-
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tion and elevations in resting Ca2  (Tong et al., 1999).
These results indicate that the MH/CCD mutations in
RyR1 result in “leaky” intracellular Ca2  release chan-
nels. In particular, the Y523S and R2163H CCD mutants
represented the most leaky channels, since they exhib-
ited the largest degree of store depletion and corre-
sponding elevations in resting Ca2 . Interestingly, our
results in dyspedic myotubes also indicate that the
Y523S and R2163H mutations result in the most severe
disruption of SR Ca2  release channel function of all
the NH2-terminal CCD mutations in RyR1. Neverthe-
less, differences in the conclusions obtained from ex-
pression of the I4897T mutation in HEK-293 cells
(Lynch et al., 1999) and dyspedic myotubes (Avila et al.,
2001a) underscores the importance of conﬁrming data
obtained in heterologous expression systems with those
observed within a skeletal muscle context.
Effects of CCD Mutations in RyR1 on Resting Ca2 
The inﬂuence of the MH/CCD mutations in RyR1 on
resting intracellular Ca2  levels is still one of the most
controversial and hotly debated issues in the ﬁeld (for
review see Mickelson and Louis, 1996). Compared with
wild-type RyR1, HEK-293 cells transfected with either
Y523S or R2163H exhibited signiﬁcantly higher resting
Ca2  levels as monitored using Fura-2 (Tong et al.,
1999). Our results indicate that dyspedic myotubes ex-
pressing certain CCD mutations in RyR1 (R164C,
R2435H, R2163H, and Y523S, but not I4898T or
I404M) exhibit signiﬁcant elevations in resting Ca2 
compared with that of wild-type RyR1 (Fig. 1 B).
Clearly, it will be important for future studies to deter-
mine whether or not resting intracellular Ca2  levels
are altered after expression of the different MH-selec-
tive mutations in RyR1 in dyspedic myotubes.
The precise mechanism(s) underlying how leaky SR
Ca2  release channels lead to long-term elevations in
resting Ca2  is still unclear. If SR Ca2  leak exceeds cal-
cium uptake and extrusion, a new dynamic equilibrium
of calcium mobilization could be established that leads
to a higher resting calcium level. However, since the
predominant Ca2  extrusion processes of the plasma
membrane (Ca2  pumps and Na/Ca2  exchangers) are
stimulated by elevations in resting Ca2 , then over
longer periods of time these transport mechanisms may
be sufﬁcient to compensate for the Ca2  leak, ultimately
resulting in a return of Ca2  toward normal levels. Un-
der such a scenario, the long-term effect of SR leak
would manifest as a similar resting Ca2  level in the face
of SR Ca2  store depletion. The caveat to this would be
the presence of restricted intracellular domains in
which Ca2  diffusion to the plasma membrane is limited
via some currently unknown mechanism (e.g., a central
core; MacLennan and Phillips, 1995; Loke and MacLen-
nan, 1998). Within such a diffusion-limited domain, in-289 Avila and Dirksen
creased SR Ca2  leak could result in localized changes
in resting Ca2 . However, elevations in global Ca2  lev-
els are found after transient expression of CCD mutant
RyR1 proteins in both dyspedic myotubes (Fig. 1 B) and
HEK-293 cells (Tong et al., 1999). Such changes in glo-
bal Ca2  levels may involve alterations in the activity of
sarcolemmal Ca2  transport mechanisms after introduc-
tion of mutant SR Ca2  release channels. For example,
changes in steady-state Ca2  inﬂux through L-type Ca2 
channels (due to differences in L-channel window cur-
rent), Ca2  release activated Ca2  channels (after store
depletion), and/or the plasma membrane Ca2  ATP-
ases (subsequent to mitochondrial dysfunction) repre-
sent a few mechanisms by which altered RyR1 function
could potentially inﬂuence sarcolemmal Ca2  transport
processes. Clearly, future investigations are required to
delineate the precise cellular mechanism(s) that under-
lies the elevation in resting Ca2  induced by certain
CCD mutations in RyR1.
Implications for the Pathophysiology of CCD 
Although diagnosis of CCD is determined through
identiﬁcation of amorphous central areas in type 1 mus-
cle ﬁbers that lack mitochondria and oxidative enzyme
activity, the underlying processes involved in the forma-
tion of central cores and their biochemical composition
is still a mystery. Global resting Ca2  levels are elevated
after transient expression of CCD mutations in RyR1 in
HEK-293 cells (Tong et al., 1999) and dyspedic myo-
tubes (Fig. 1 B). Consequently, long-term changes in
Ca2 -regulated gene transcription (Ginty, 1997; Avila et
al., 2001b) may lead to alterations in muscle ﬁber struc-
ture and function. However, our observation that the
I4897T CCD mutation does not lead to a change in rest-
ing Ca2  levels argues against the notion that an in-
crease in resting Ca2  is an absolute requirement for
core formation. Rather, our data indicate that a reduc-
tion in the magnitude of voltage-gated Ca2  transients,
which is a common feature for both NH2-terminal and
COOH-terminal mutants, may contribute to core for-
mation. However, a reduction in Ca2  transient magni-
tude alone may not be sufﬁcient, since central cores are
not observed for other conditions in which skeletal mus-
cle activity is markedly compromised (e.g., other debili-
tating muscular dystrophies, after paralysis, etc.). Thus,
the CCD mutations are likely to alter other factors that
also contribute to the pathogenesis of central cores. A
recent study has identiﬁed a functional mitochondrial
ryanodine receptor that participates in dynamic changes
in mitochondrial Ca2  levels in cardiac ventricular myo-
cytes (Beutner et al., 2001). If ryanodine receptors are
also found to be present in skeletal muscle mitochon-
dria, then the expression of mutant RyR1s with altered
Ca2  permeability properties may result in dire conse-
quences for the proper control of intramitochondrial
Ca2  levels. Subsequent alterations in mitochondrial
Ca2  homeostasis and Ca2 -dependent energy metabo-
lism that leads to an increased generation of reactive ox-
ygen species and mitochondrial dysfunction (Gunter et
al., 1994) could explain the loss of oxidative enzyme ac-
tivity within the core regions. Clearly, it will be impor-
tant for future work to determine the downstream
mechanisms and processes that underlie core forma-
tion. Since it is unlikely that transient expression ap-
proaches will recapitulate the process of core forma-
tion, the answer to this question must likely await the
development of appropriate animal models for CCD.
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